Review Article

Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target

Authors: Xin Zhang1,2, Can Hu1,2, Hai-ming Wu1,2, Zhen-guo Ma1,2, Qi-zhu Tang1,2
1 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China
2 Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan 430060, China
Correspondence to: Zhen-guo Ma: zhengma@whu.edu.cn, Qi-zhu Tang: qztang@whu.edu.cn,
DOI: 10.1038/s41401-020-00557-5
Received: 4 August 2020
Accepted: 13 October 2020
Advance online: 19 November 2020

Abstract

Cardiovascular and metabolic diseases are the leading causes of death and disability worldwide and impose a tremendous socioeconomic burden on individuals as well as the healthcare system. Fibronectin type III domain-containing 5 (FNDC5) is a widely distributed transmembrane glycoprotein that can be proteolytically cleaved and secreted as irisin to regulate glycolipid metabolism and cardiovascular homeostasis. In this review, we present the current knowledge on the predictive and therapeutic role of FNDC5 in a variety of cardiovascular and metabolic diseases, such as hypertension, atherosclerosis, ischemic heart disease, arrhythmia, metabolic cardiomyopathy, cardiac remodeling, heart failure, diabetes mellitus, and obesity.
Keywords: cardiovascular and metabolic diseases; FNDC5; biomarker; therapeutic target

Article Options

Download Citation

Cited times in Scopus